Genomics of high-risk blood and lymphoid cancer

We aim to fully understand blood and lymphoid cancers that resist conventional treatments or relapse after treatment.
We work by combining multi-omics techniques, often simultaneously in individual cancer cells and repeating measurements serially across treatment timepoints.
Our goal is to achieve precise identification of high-risk features earlier in the disease course, and to identify new approaches for targeting the cells and pathways that drive relapse.